Novartis announced deals to acquire Pikavation Therapeutics and related PI3Kα programs in transactions worth up to $3 billion, including $2 billion upfront for SNV4818. The company says SNV4818 is a pan‑mutant selective PI3Kα inhibitor in Phase I/II that aims to target tumor PIK3CA mutations while sparing wild‑type enzyme to improve tolerability and combination potential in HR+/HER2‑ breast cancer. Synnovation (Pikavation’s parent) will retain other subsidiaries while Novartis takes over clinical development and global commercialization. Novartis framed the purchase as a precision‑medicine play to strengthen its breast cancer portfolio and enable combinations with endocrine and CDK inhibitors; Synnovation executives highlighted the pair’s mutant‑selective chemistry and preclinical activity.